# Clinical Trials Data EGFR - Document 124

# The Roles of Neutrophil Elastase in Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01360931

"eligibilityCriteria": "Inclusion Criteria:\n\n\* All subjects undergoing clinical diagnostic or therapeutic procedures, including:\n\n 1. Fibreoptic bronchoscopy or pleuroscopy\n 2. Diagnostic or Therapeutic pleurocentesis AND who are mentally fit to give informed consent for donation of clinical specimens\n\nExclusion Criteria:\n\n\* Patients who cannot give written informed consent or refuse to give such consent for participation in this study",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Subjects undergoing diagnostic bronchoscopy",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the inclusion and exclusion criteria focus primarily on the procedural context (i.e., subjects undergoing specific diagnostic or therapeutic procedures) and the ability to give informed consent. There is no mention of eligibility being influenced by specific genetic mutations, such as the EGFR gene mutation. Therefore, a patient with an EGFR gene mutation would not be excluded solely based on this mutation and would likely be eligible for the trial, provided they meet the other listed criteria (undergoing the relevant procedures and able to give informed consent).